Thymosin beta-4 is a naturally occurring 43-amino-acid protein found in most human cells and body fluids. Its best-established molecular job is binding monomeric, or G-actin, and helping regulate how much actin is available to build cell filaments. TB-500 is related, but it is not another name for the whole protein: it is a synthetic seven-amino-acid fragment centered on residues 17–23, the LKKTETQ actin-binding region. That size difference matters. Studies of full-length TB4 cannot automatically establish what the shorter TB-500 fragment does in people.
What thymosin beta-4 does inside cells
Actin is often described as cellular scaffolding, but it is not static. Cells continually assemble actin monomers into filaments and take those filaments apart. That remodeling helps a cell hold its shape, divide, and move. It is especially relevant when epithelial cells, immune cells, and blood-vessel cells migrate through tissue during repair.
Full-length Tβ4 binds G-actin in a one-to-one complex and keeps part of that actin pool from polymerizing too soon. A laboratory study of the 43-amino-acid peptide found that it bound actin monomers and inhibited filament formation; changing one oxidized residue reduced that polymerization-inhibiting capacity about twentyfold (Heintz et al., European Journal of Biochemistry 1994). The useful idea is balance, not acceleration: cells need actin available, but they also need its assembly controlled in space and time.
Tβ4 has also been studied in signaling connected with cell survival, inflammation, blood-vessel growth, and extracellular-matrix remodeling. Those pathways help explain the breadth of the parent-molecule literature, but they do not make every proposed clinical use established.
Why actin connects TB4 to wound repair
Wound repair depends on several coordinated events. Cells must move into a gap, new surface tissue must form, collagen must be deposited, and small blood vessels must reorganize. Actin dynamics sit underneath much of that movement, which is why Tβ4 research expanded from cell biology into skin, corneal, and cardiac models.
A 2003 study tested both full-length Tβ4 and the seven-amino-acid LKKTETQ sequence in diabetic and aged mice. The researchers reported that the parent promoted dermal repair in those models and that the short actin-binding sequence promoted repair in aged mice at a level comparable with the parent in that experiment (Philp et al., Wound Repair and Regeneration 2003). This is important fragment evidence. It is still animal evidence, not a controlled human trial of TB-500.
Thymosin beta-4 and TB-500 are related, not identical
The names are often collapsed online, but the molecules and their evidence records are different. Peer-reviewed analytical work identified TB-500 as N-acetylated LKKTETQ, the active region spanning residues 17–23 of Tβ4 (Ho et al., Journal of Chromatography A 2012).
| Feature | Full-length thymosin beta-4 | TB-500 |
|---|---|---|
| Length | 43 amino acids | 7 amino acids |
| Sequence scope | Entire endogenous protein | Ac-LKKTETQ, residues 17–23 |
| Relationship to actin | Contacts actin across a broader molecular surface | Centers on the recognized actin-binding region |
| Research record | Cell, animal, and limited human studies across several formulations | Primarily laboratory and animal work; direct human fragment data are limited |
| Fair conclusion | The parent has multiple active regions and studied functions | The fragment may retain activity linked to its sequence, but it is not the whole parent |
That distinction also matters for blends. Promise's Wolverine formulation pairs BPC-157 with TB-500 in one compounded prescription. It does not contain full-length Tβ4, and combining two peptides does not erase the evidence limits of either one.
What the human research actually studied
Human research exists for full-length Tβ4, but it is small and formulation-specific. A phase 2 trial enrolled nine people with severe dry eye at two U.S. sites and evaluated 0.1% Tβ4 eye drops for 28 days, followed by 28 days of observation. The investigators reported improvements at selected time points in ocular discomfort and corneal staining compared with vehicle control (Sosne et al., Cornea 2015). Nine participants cannot establish a broad tissue-repair effect, and an ophthalmic solution is not evidence for an injected fragment.
A later phase III trial studied 18 people with neurotrophic keratopathy, again using 0.1% full-length Tβ4 eye drops. Complete healing at four weeks occurred in 6 of 10 participants given Tβ4 and 1 of 8 given placebo, but the primary comparison missed statistical significance at p=0.0656. A sustained-healing measure two weeks later was significant at p=0.0359 (Sosne et al., International Journal of Molecular Sciences 2022). The result is promising but mixed, and it still does not test TB-500.
A 2021 phase I study evaluated intravenous recombinant human Tβ4 in healthy volunteers. It included 54 participants in single-dose cohorts and 30 in multiple-dose cohorts, and its purpose was safety, tolerability, and pharmacokinetics rather than proof of repair in patients (Wang et al., Journal of Cellular and Molecular Medicine 2021). Again, this was full-length recombinant Tβ4.
Cardiac research illustrates the same evidence boundary. In a 2004 mouse study, full-length Tβ4 was associated with cardiomyocyte migration and survival signaling after coronary artery ligation, along with improved cardiac function in that model (Bock-Marquette et al., Nature 2004). That is a mechanistic and preclinical finding. It is not evidence that TB-500 prevents or treats heart disease in people.
What parent-molecule research does not prove about TB-500
A fragment can preserve a meaningful binding motif without reproducing every property of its parent. The remaining 36 amino acids may affect structure, stability, metabolism, distribution, or interaction with other molecules. Route and formulation matter too: an eye drop, a topical wound preparation, an intravenous recombinant protein, and a compounded injectable fragment are not interchangeable interventions.
This is the central reading rule for TB4 claims: first identify which molecule was studied, then the biological model and formulation. A cell experiment can explain a mechanism. An animal study can justify further research. Neither establishes a patient outcome. Even the available human Tβ4 trials do not automatically cross the gap to TB-500.
For the practical questions this page intentionally leaves alone, see the focused guides to TB-500 and injury-recovery research, TB-500 side effects, and how BPC-157 compares with TB-500.
What provider involvement changes
Clinical review does not turn limited evidence into strong evidence. It does create accountability around medical history, current medications, whether a request is coherent, and what follow-up is needed. Whether a prescribed compounded TB-500 fragment is appropriate is a decision for the patient and the licensed prescriber.
At Promise, a licensed provider reviews every request and prescribes TB-500 only when it is medically appropriate; not everyone qualifies. If it is prescribed, the provider sets the actual protocol rather than relying on a schedule inferred from parent-molecule studies.
The three details that keep the evidence straight
A clear account of thymosin beta-4 should always preserve three details: the sequence, the model, and the formulation. The sequence tells you whether the study used all 43 amino acids or the seven-residue fragment. The model separates cells and animals from people. The formulation prevents an eye-drop or recombinant-protein result from being treated as evidence for a compounded injectable.
That leaves a precise summary. Thymosin beta-4 is the naturally occurring parent with the wider research record. TB-500 is a shorter synthetic fragment built around its actin-binding region. They are related by sequence and mechanism, but they are not the same molecule, and their evidence should not be reported as though they were.